Molecule name | Selectivity | Development status | Maximum development phase | FDA approved | BBB penetration | Half-life (h) |
---|---|---|---|---|---|---|
Entinostat | HDAC 1, 3 | Investigational | 3 | 0 | Limited/poor | 33–150 [63] |
JNJ-26481585 | Pan HDAC | Investigational | 2 | 0 | Not reported | 8,8 [64] |
Pracinostat | Pan HDAC | Investigational | 2 | 0 | Yes in mice | 5,6–8,9 [65] |
Panobinostat | Pan HDAC | Marketed | 4 | 1 | Limited | 16 [66] |
Belinostat | Pan HDAC | Marketed | 4 | 1 | Limited | 1,5 [67] |
Trichostatin A | Pan HDAC | Investigational | 1 | 0 | Limited | Not determined |
Givinostat | Pan HDAC | Investigational | 3 | 0 | Yes | 6,9 [68] |
Vorinostat | Pan HDAC | Marketed | 4 | 1 | Yes | 1–2 [69] |
Abexinostat | Pan HDAC | Investigational | 1 | 0 | Yes | 4 [70] |
CUDC-101 | Pan HDAC, Her, EGFR | Investigational | 1 | 0 | Not reported | 4,4 [71] |
Dacinostat | Pan HDAC | Investigational | 2 | 0 | Not reported | 6–15 [72] |
Mocetinostat | Class I selective | Investigational | 2 | 0 | Yes in mice | 7–11 [73] |
CUDC-907 | Pan HDAC, PI3K | Investigational | 2 | 0 | < 10% in mice | 3 [74] |
Resminostat | HDAC 1, 3, 6 | Investigational | 2 | 0 | Not reported | 3 [75] |
Tacedinaline | Class I selective | Investigational | 3 | 0 | 15–45% in monkey | 8,5–10 [76] |
RG2833 | HDAC 1, 3 | Investigational | 1 | 0 | Yes in mice | 6–10 [77] |
M344 | Pan HDAC | Discovery | Â | 0 | Yes in mice | Not determined |
Domatinostat | Pan HDAC, LSD1 | Investigational | 1 | 0 | Not reported | 20 [78] |
Scriptaid | Pan HDAC | Discovery | Â | 0 | Not reported | Not determined |
Rocilinostat | HDAC 6 | Investigational | 2 | 0 | Not reported | 3 [79] |